Skip to main content
. 2019 Dec 17;122(4):517–527. doi: 10.1038/s41416-019-0681-5

Fig. 1. Drug-repurposing screen identifies drugs that increase docetaxel efficacy.

Fig. 1

a Venn diagram of screen results. The percentage growth inhibition for each drug in combination with docetaxel relative to the DMSO control was calculated. The number of drugs with a ≥ 10% increase is shown for each concentration. b CP2 cells were treated with the indicated anthelmintics, combined with either docetaxel or DMSO. The percentage growth inhibition for each drug in combination with docetaxel relative to the DMSO control was calculated. n = 3 (technical replicates), mean values ± SD are shown, analysed by two-way ANOVA with Sidak’s multiple comparisons test, *p < 0.01, **p < 0.001, ***p < 0.0001. c CP2, SP1 and LNCaP cells were treated with mebendazole at the indicated concentrations or DMSO control, in combination with docetaxel at a range of concentrations for 48 h. Cells were fixed, stained with DAPI and cytotoxicity quantified by nuclear count using High Content Imaging Analysis (Operetta, Perkin Elmer). The percentage growth inhibition relative to the DMSO control for each docetaxel concentration (left panels), and the percentage cell survival after treatment with the target drugs alone (right panels) were calculated. n = 3 (technical replicates), mean values ± SD are shown.